Mechanism of Cordyceps militaris against non-small cell lung cancer: based on serum metabolomics.
10.19540/j.cnki.cjcmm.20220613.702
- Author:
Ying-Ying LU
1
;
Xiao HUANG
1
;
Zi-Chen LUO
2
;
Ming-Yuan QI
3
;
Jin-Jun SHAN
4
;
Wen ZHANG
1
;
Liu-Qing DI
1
Author Information
1. School of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023, China Jiangsu Engineering Research Center for Efficient Delivery System of TCM Nanjing 210023, China.
2. School of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023, China Jiangsu Engineering Research Center for Efficient Delivery System of TCM Nanjing 210023, China Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine Nanjing 210023, China.
3. Hunan Yandi Biological Engineering Co., Ltd. Zhuzhou 412007, China.
4. School of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023, China Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine Nanjing 210023, China.
- Publication Type:Journal Article
- Keywords:
Cordyceps;
Cordyceps militaris;
non-small cell lung cancer;
serum metabolomics;
tumor
- MeSH:
Alanine/metabolism*;
Animals;
Arginine/metabolism*;
Aspartic Acid;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Cisplatin/pharmacology*;
Cordyceps;
Glutamic Acid;
Glutamine;
Glyoxylates/metabolism*;
Humans;
Lung Neoplasms/drug therapy*;
Metabolomics/methods*;
Mice;
Mice, Nude;
Nitrogen/metabolism*;
Phenylalanine/metabolism*;
RNA, Transfer/metabolism*;
Tryptophan/metabolism*;
Tyrosine/metabolism*
- From:
China Journal of Chinese Materia Medica
2022;47(18):5032-5039
- CountryChina
- Language:Chinese
-
Abstract:
This study investigated the potential mechanism of Cordyceps militaris(CM) against non-small cell lung cancer(NSCLC) based on serum untargeted metabolomics. Specifically, Balb/c nude mice were used to generate the human lung cancer A549 xenograft mouse model. The tumor volume, tumor weight, and tumor inhibition rate in mice in the model, cisplatin, Cordyceps(low-, medium-, and high-dose), and CM(low-, medium-, and high-dose) groups were compared to evaluate the influence of CM on lung cancer. Gas chromatography-mass spectrometry(GC-MS) was used for the analysis of mouse serum, SIMCA 13.0 for the compa-rison of metabolic profiles, and MetaboAnalyst 5.0 for the analysis of metabolic pathways. According to the pharmacodynamic data, the tumor volume and tumor weight of mice in high-dose CM group and cisplatin group decreased as compared with those in the model group(P<0.05 or P<0.01). The results of serum metabolomics showed that the metabolic profiles of the model group were significantly different from those of the high-dose CM group, and the content of endogenous metabolites was adjusted to different degrees. A total of 42 differential metabolites and 7 differential metabolic pathways were identified. In conclusion, CM could significantly inhibit the tumor growth of lung cancer xenograft mice. The mechanism is the likelihood that it influences the aminoacyl-tRNA biosynthesis, the metabolism of D-glutamine and D-glutamate, metabolism of alanine, aspartate, and glutamate, metabolism of glyoxylate and dicarboxylic acid, biosynthesis of phenylalanine, tyrosine, and tryptophan, arginine biosynthesis as well as nitrogen metabolism. This study elucidated the underlying mechanism of CM against NSCLC from the point of metabolites. The results would lay a foundation for the anticancer research and clinical application of CM.
